NLSI yields 1.90% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, NLSI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NLSI + PFE for your $10,000?
NLSI implements a long short equity strategy combined with an options overlay to generate monthly income while maintaining exposure to US equities. The fund holds long and short positions in mid- and large-cap US exchange-traded equities, with portfolio construction guided by a proprietary process that differentiates companies with stronger expected fundamentals from those viewed less favorably. Long positions are built through bottom-up security selection, while short positions target equities with weaker balance sheets, cash flow, or sector conditions. Alongside the equity portfolio, the fund employs an options strategy using index-based put spreads, consisting of written and purchased put options, to generate option premium and support income generation. The options positions may be actively adjusted prior to expiration and are designed to complement the equity exposures rather than hedge them outright. The fund maintains a consistent long short structure with defined gross exposure targets and may hold cash and short-term instruments to support portfolio operations and short positions.
Full NLSI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.